Cancer Family
Connective and Soft Tissue Neoplasm
CI-CAN-00000010Explore in graph →
Non-malignant849 active trials17 approved drugs339 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000010Explore in graph →
Clinical trials
3,878 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01061840 | Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer | completed | Phase 1 | 100 | Gradalis, Inc.INDUSTRY | 1 | Mar 15, 2022 | clinicaltrials |
| NCT05042934 | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT01057121 | Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT02982941 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | completed | Phase 1 | 25 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02630368 | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)(METROmaJX) | unknown | Phase 1 / Phase 2 | 197 | Institut BergoniéOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02054104 | Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | terminated | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05080621 | Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) | withdrawn | Phase 1 / Phase 2 | 0 | Deciphera Pharmaceuticals, LLCINDUSTRY | 0 | Jan 5, 2022 | clinicaltrials |
| NCT04648826 | Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2021 | clinicaltrials |
| NCT03042819 | Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas | completed | Phase 1 | 25 | University Health Network, TorontoOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT01294670 | Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Nov 18, 2021 | clinicaltrials |
| NCT00000987 | A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS | completed | Phase 1 | 36 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00001113 | A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma | completed | Phase 1 | 48 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00000660 | Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 24 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000681 | A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma | completed | Phase 1 | 24 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000725 | A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 56 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000763 | A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 42 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000694 | A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 18 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 2, 2021 | clinicaltrials |
| NCT00000695 | Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma | completed | Phase 1 | 36 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 2, 2021 | clinicaltrials |
| NCT00000954 | A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma | completed | Phase 1 | 72 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 29, 2021 | clinicaltrials |
| NCT00000769 | A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma | completed | Phase 1 | 48 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 28, 2021 | clinicaltrials |
| NCT03056599 | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma | completed | Phase 1 | 23 | Presage BiosciencesINDUSTRY | 1 | Sep 24, 2021 | clinicaltrials |
| NCT02471716 | Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor(FPA008-002) | completed | Phase 1 / Phase 2 | 66 | Five Prime Therapeutics, Inc.INDUSTRY | 6 | Aug 31, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT04388371 | Glutamine PET Imaging in LAM | completed | Phase 1 | 5 | Vanderbilt University Medical CenterOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT01275222 | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Jun 25, 2021 | clinicaltrials |
| NCT02164240 | Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST(SURE) | completed | Phase 1 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 14, 2021 | clinicaltrials |
| NCT04556669 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT02888665 | Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT04886765 | A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma | unknown | Phase 1 / Phase 2 | 238 | AlaMab Therapeutics (Shanghai) Inc.INDUSTRY | 0 | May 14, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03158103 | A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | completed | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02398058 | Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)(TOMAS) | completed | Phase 1 | 50 | Italian Sarcoma GroupNETWORK | 1 | Apr 14, 2021 | clinicaltrials |
| NCT03730077 | FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas | terminated | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT04798326 | Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults(MW032) | completed | Phase 1 | 120 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 15, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT00258687 | Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | terminated | Phase 1 | 35 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT01833520 | Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma | completed | Phase 1 / Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT02748135 | A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma | completed | Phase 1 | 18 | Oncurious NVINDUSTRY | 1 | Jan 13, 2021 | clinicaltrials |
| NCT02044120 | ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma | completed | Phase 1 | 34 | Sarcoma Alliance for Research through CollaborationOTHER | 2 | Jan 12, 2021 | clinicaltrials |
| NCT03342859 | Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned | terminated | Phase 1 | 10 | BayerINDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT03139331 | PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma | completed | Phase 1 | 16 | University of California, San FranciscoOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03782363 | Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.(CAST) | withdrawn | Phase 1 | 0 | Italian Sarcoma GroupNETWORK | 1 | Dec 22, 2020 | clinicaltrials |
| NCT01338831 | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | completed | Phase 1 | 73 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT01024907 | Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas | completed | Phase 1 / Phase 2 | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02343172 | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | completed | Phase 1 | 74 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Mar 15, 2022source: clinicaltrials